Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Subscribe To Our Newsletter & Stay Updated
